FMP

FMP

Enter

HALO - Halozyme Therapeutic...

photo-url-https://images.financialmodelingprep.com/symbol/HALO.png

Halozyme Therapeutics, Inc.

HALO

NASDAQ

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

62.27 USD

1.21 (1.94%)

HALO Financial Statements

Quarter

2024 Q4

2024 Q3

2024 Q2

2024 Q1

Total Revenue

298.01M

290.08M

231.35M

195.88M

Cost of Revenue

42.05M

49.43M

57.37M

46.09M

Gross Profit

255.95M

240.66M

173.98M

149.79M

Operating Expenses

80.45M

77.46M

56.75M

54.24M

Research and Development

20.44M

18.46M

21.04M

19.11M

Selling, General & Administrative Expenses

42.25M

41.24M

35.71M

35.13M

Selling & Marketing Expenses

0

0

0

0

General & Administrative Expenses

0

0

0

0

Other Expenses

17.76M

17.76M

17.76M

17.76M

Operating Income

175.5M

163.2M

117.23M

95.54M

Total Other Income/Expenses Net

2.71M

1.95M

508k

486k

Income Before Tax

178.21M

165.15M

117.74M

96.03M

Income Tax

41.2M

28.14M

24.5M

19.2M

Net Income

137.01M

137.01M

93.25M

76.82M

Basic EPS

1.08

1.08

0.73

0.61

EPS Diluted

1.06

1.05

0.72

0.6

Basic Average Shares

126.41M

126.85M

127.12M

126.94M

Diluted Average Shares

128.98M

130.13M

129.22M

128.89M

EBITDA

203.17M

190.03M

137.6M

115.75M

All figures are in USD.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2024 © Financial Modeling Prep